AbbVie

News

NHS trumpets Hep C deal, quietly drops 2025 elimination targ...

NHS England has announced a deal with AbbVie, Gilead, and Merck, Sharpe and Dohme (MSD) that aims to eliminate hepatitis C from the country - although it has had to drop a 2025 target

News

AbbVie gets crucial US approval for psoriasis drug Skyrizi

With one eye on life without its ageing $20 billion-a-year blockbuster Humira, AbbVie has got its psoriasis drug Skyrizi approved in the US.

News

AbbVie's psoriasis drug Skyrizi approved in Japan

AbbVie’s hotly anticipated psoriasis drug Skyrizi (risankizumab) has been approved in Japan, the first country to okay this potential blockbuster.

News

Question marks over AbbVie/Roche's venetoclax after safety s...

AbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a higher proportion of deaths was observed in patients receiving it tha

News

Takeda's Entyvio outperforms AbbVie's Humira in GI trial

Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis.

News

AbbVie/Roche seek first-line CLL use for Venclexta combo

AbbVie and Roche’s Venclexta is making headway as a second-line chronic lymphocytic leukaemia (CLL) treatment, and a new US filing could extend its use into the first-line setting.

NHS trumpets Hep C deal, quietly drops 2025 elimination targ...

AbbVie gets crucial US approval for psoriasis drug Skyrizi

AbbVie's psoriasis drug Skyrizi approved in Japan

Question marks over AbbVie/Roche's venetoclax after safety s...

Takeda's Entyvio outperforms AbbVie's Humira in GI trial

AbbVie/Roche seek first-line CLL use for Venclexta combo

ASH: AstraZeneca's dual-wielding CAR-T shows promise

How to meet your physicians where they are online

AbbVie

Editor's Picks